Elicio Therapeutics, Inc.
ELTX
$11.68
-$0.50-4.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.15% | -2.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.91% | -20.28% | |||
| Operating Income | -9.91% | 20.28% | |||
| Income Before Tax | 23.46% | 4.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 23.46% | 4.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.46% | 4.53% | |||
| EBIT | -9.91% | 20.28% | |||
| EBITDA | -9.97% | 20.34% | |||
| EPS Basic | 17.60% | 8.15% | |||
| Normalized Basic EPS | 17.59% | 11.63% | |||
| EPS Diluted | 17.60% | 8.15% | |||
| Normalized Diluted EPS | 17.59% | 11.63% | |||
| Average Basic Shares Outstanding | -7.10% | 3.94% | |||
| Average Diluted Shares Outstanding | -7.10% | 3.94% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||